Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary
- PMID: 30195449
- DOI: 10.1053/j.gastro.2018.08.043
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary
Abstract
Thiopurines (azathioprine, mercaptopurine, thioguanine) and methotrexate are widely used in a variety of clinical management scenarios for ulcerative colitis and Crohn's disease. With the introduction of biologic therapies over the last 2 decades, controversies have emerged as to how these immunomodulators should be used in clinical practice, either alone as monotherapies or in combination with biologic therapies. Here, we provide a summary of evidence and our interpretations regarding how physicians can or should incorporate these agents into clinical practice. We have organized the review into sections regarding their utility as monotherapy or as combination therapy with biologics and safety considerations. Clinical pharmacologic considerations are important regarding both efficacy and safety.
Keywords: Crohn's; Immunomodulators; Inflammatory Bowel Disease; Ulcerative Colitis.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones.Gastroenterology. 2019 Jan;156(1):11-14. doi: 10.1053/j.gastro.2018.11.039. Epub 2018 Nov 22. Gastroenterology. 2019. PMID: 30472233 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical